Beyond Avoidance: Omalizumab and the Evolving Care of Pediatric Food Allergy

Nathan Hinkle — Fri, 09 Oct 2026 05:00:00 +0000

Date Added:

October 9, 2026

Journal/Publication:

Pediatric Annals

Publisher:

SLACK Incorporated

Publication Date:

October 1, 2026

Issue:

Volume:

Pages:

e374-377

URL:

Beyond Avoidance: Omalizumab and the Evolving Care of Pediatric Food Allergy

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

https://doi.org/10.3928/19382359-20260908-02

Keywords

Pediatric Food Allergies

omalizumab

children

MeSH

Omalizumab* / therapeutic use

Food Hypersensitivity* / diagnosis

allergens

RPR Commentary: Advice regarding how to evaluate and manage food allergies in children. James W. Mold, MD, MPH

View

Food allergy is familiar territory in primary care, but the therapeutic landscape is changing quickly. For years, our conversations with families centered on avoidance, label reading, emergency action plans, and ready access to epinephrine. Those remain essential. Yet, newer therapies now offer something different: the possibility of increasing the amount of allergen needed to trigger a reaction and thereby reducing some of the risk associated with accidental exposure. The recent randomized clinical trial by Wood et al.1 brings that shift into especially sharp focus. In patients with multiple food allergies, continued omalizumab treatment was more successful than omalizumab-facilitated multiallergen oral immunotherapy in the intention-to-treat analysis, largely because adverse events and treatment discontinuations limited completion of oral immunotherapy.

Author/s:

Lolita Alocer Alkureishi, Sai R. Nimmagadda, Joseph R. Hageman

Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment

Alex Haga — Sun, 04 Aug 2024 18:10:28 +0000

Date Added:

August 4, 2024

Journal/Publication:

Lancet

Publication Date:

July 27, 2024

Issue:

10450

Volume:

404

Pages:

393-404

URL:

Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment

Type:

Meta-analyses, Reviews, and Guidelines

Format:

Article

DOI (1):

10.1016/S0140-6736(24)00852-3

Keywords

urticaria

chronic urticaria

omalizumab

PMID (1):

39004090

MeSH

Chronic Urticaria* / drug therapy

Agammaglobulinaemia Tyrosine Kinase / antagonists & inhibitors

Cyclosporine / therapeutic use

Mast Cells / drug effects

Omalizumab* / therapeutic use

A review of what we know and don't know about chronic urticaria and its treatment. James W. Mold, MD, MPH

Free full text

View

Chronic urticaria is a common and debilitating mast cell-driven skin disease presenting with itchy wheals, angio-oedema, or both. Chronic urticaria is classified as spontaneous (without definite triggers) and inducible (with definite and subtype-specific triggers; eg, cold or pressure). Current management guidelines recommend step-up administration of second-generation H1-antihistamines to four-fold the approved dose, followed by omalizumab and ciclosporin. However, in many patients, chronic urticaria does not respond to this linear approach due to heterogeneous underlying mechanisms. A personalised endotype-based approach is emerging based on the identification of autoantibodies and other drivers of urticaria pathogenesis. Over the past decade, clinical trials have presented promising options for targeted treatment of chronic urticaria with the potential for disease modification, including Bruton's tyrosine kinase inhibitors, anti-cytokine therapies, and mast cell depletion. This Therapeutics article focuses on the evidence for these novel drugs and their role in addressing an unmet need for personalised management of patients with chronic urticaria.

Author/s:

Torsten Zuberbier, Luis Felipe Ensina, Ana Giménez-Arnau, Clive Grattan